Protara Therapeutics (TARA) stock

Market cap $194M

$2.76

-9.51%

Market closed. Prices as of Thursday's close.

Quality Score

-7

Poor

In its industry

#260of 276

Biotech

Checks firing

1of 14

Trending down

From 52-week high

-64.7%

Below the 200-day

Next2H 2026“…3 clinical trial, is ongoing, and the Company expects to report interim results in the second half of 2026…”Trial data · 8-K, May 13

Cash$142M, about 8 quarters (2 years) at the last year's spendingOn Jun 30 · the company says “into 2028”

Follow TARA's trial news. Pro members can get an alert when Protara Therapeutics files news, and see its trials, share raises, and its CEO's filings.

Get an optional alert when TARA files news on its trialsFree for 24 hours. No account needed.

Cash$142M, about 8 quarters (2 years) at the last year's spendingOn Jun 30 · the company says “into 2028”

Pipeline and cash

What's next for TARA, and how long its cash lasts

From Protara Therapeutics’s SEC filings and ClinicalTrials.gov: the company’s own words, the registry’s dates, and arithmetic, not a forecast. Companies often miss their own dates.

Next step the company has named

2H 2026“registrational Phase 3 clinical trial, is ongoing, and the Company expects to report interim results in the second half of 2026.”Trial data · 8-K, May 13

What it means: the first look at a trial’s main results, as the company reports them.

A trial underway: THRIVE-3Phase 2/3 · Recruiting · 129 people · main data estimated Mar 2028 · NCT06910943

3 more trials, 1 with data due this year, 2 more milestones and 28 filings, for Pro members.

Cash runway Jun 30 balance sheet

About 8 quarters

$142M in cash and short-term investments, at its spending over the last year

What it means: how long the cash would last at the same pace, before any new money. The company's own estimate is “into 2028” (8-K, May 13).

For Pro members: the cash used each quarter, and the math.

Dilution on the horizon

Shelf registration (S-3, filed Nov 3, 2023)
At-the-market share sales program (424B5, filed May 28, 2026)

A shelf lets a company sell shares later; an at-the-market program sells them into the market over time. Neither is a sale by itself.

For Pro members: 3 raises and their amounts, and the share count against a year ago.

Insiders

CEO Jesse Shefferman sold 215,687 shares on Jun 29. 2 more insider trades this year.

From their own Form 4 filings: buys and sales in the market, not awards or shares withheld for tax.

Get an optional alert when Jesse Shefferman buys or sells

For Pro members: every trade, and Jesse Shefferman’s 15 filings and quotes.

Get an optional alert when TARA files news on its trialsFree for 24 hours. No account needed.

See every upcoming FDA date →

Biotech dates

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their own filings, soonest first and small companies first.

DateStockDrug

In 28 daysFDA decisionIn 28 days · FDA decisionINOInovio PharmaceuticalsINO-3107INOInovio Pharmaceuticals · $122MINO-3107Under FDA review
In 39 daysANDA decisionIn 39 days · ANDA decisionNRXPNRX PharmaceuticalsDrug not namedNRXPNRX Pharmaceuticals · $130MDrug not namedA generic, under FDA review
In 51 daysFDA decisionIn 51 days · FDA decisionCAPRCapricor TherapeuticsDrug not namedCAPRCapricor Therapeutics · $486MDrug not namedUnder FDA review

8 more FDA dates and 107 trial data dates in the next 60 days. Pro members see every one, with the cash against its date and an optional alert before it. Get in free →

Why TARA is down

Protara Therapeutics fell 17.6% over the five sessions to Oct 1.

Biotech stocks fell a median 3.2% and the S&P 500 fell 0.4% in those sessions; Protara Therapeutics fell 17.6%.

Sources: Price history, Oct 1, 2026

1 more driver and the timeline, for Pro members

Quality Score

Why TARA scores -7

PoorTrending down, 1 of 14 checks firingWhat the Quality Score means

Below -5, off the left end of the scale. Poor is below 0. Average starts at 6, Above Average at 11, Excellent at 15, and Exceptional at 20.

-7 is below -5, off the left end of the scale.

−2Long-term trend below a falling 200-⁠day average, down over one year
−2Dilution 44.3% more shares outstanding than a year agoNew shares over the year: -1 at 10% more, -2 at 25% more.

Chart checks adds
Size subtracts
Profit subtractsRead on the last four quarters against the four before, or the last full year where no quarters are filed.
Volatility subtractsA daily range of 5% or more with nothing behind it (no profit or cash flow, sales shrinking, or 10% more shares outstanding with no free cash flow): -1, or -2 from 8%.
Cash flow subtracts-1 when free cash flow over the last four quarters is negative.

No effect today: Run-up, Growth, Persistence, and News.

What every line is worth, and the reason behind it, on TARA and every other stock.Get in free →

Price, score, chart checks, and the industry rank are from a snapshot taken at 1:11 AM ET, at least 15 minutes behind. How we rank stocks.

What's next

Expected to report Tue Nov 10, before the open

After its last 4 reports it closed +0.3% on average, higher 2 of 4 times.

What would turn TARA's score around: 8 things, for Pro members

Alert me when TARA's Quality Score turns up

Free for 24 hours. No account needed. Then keep going with a free account.

Pro

Here is what Pro members see.

Every stock gets a card like this one, and a page with its price in real time, every line of its score, the chart, and its filings.

A Pro member's scanner card for AMD: the Quality Score badge, the rank in the scan and in its industry, the chart checks bar, three plain lines on its strength, notable holders, and early signs, and pills for size, volume, RSI, and short interest — A card on the scanner, shown on AMD

A Pro member's stock page for AMD: the Quality Score with its rank, the checks firing, and the reason behind it, the live price, and the chart — A stock page

The scanner a Pro member sees: every stock as a card with its Quality Score, rank, and chart checks bar, and the watchlist — The scanner

The 14 checks

TARA has 1 of 14 checks firing

One per group is shown here.

Trend1 of 5 shown

MA FAN 21 EMA W.EMA HH/HL 52W HI

Averages stacked in order, price near its high.

Volume1 of 3 shown

VOL VDU U/D VOL

Heavy volume on the run, quiet volume at rest.

Tight range1 of 3 shown

ATR SQZ SQUEEZE NR7

The daily range is tight against its own recent history.

Buying1 of 3 shown

OBV+CLOSE HI SPRING

Closes near the high, and buyers step in on dips.

The other 10 checks on TARA, and all 14 on every stock.Get in free →

Also on the chart

Not scored

Shown for reference. None of these counts toward the Quality Score: in our tests on 20 years of daily prices, none of them improved it.

RSI 1420.1
Below 30.
MACD (12, 26, 9)Below signal
Crossed below its signal line 12 sessions ago.
50-day average$3.80
The price is 27.4% below it.
200-day average$4.86
The price is 43.2% below it. The 50-day is below the 200-day, since May 26.
ADX 1425.6
25 or more, with +DI below -DI.
Support
No swing low under the price in the last year.
Resistance$4.01
Swing high from Sep 14, 45.5% above the price.
Bollinger Bands (20, 2)Below
The bands run from $2.93 to $4.21.
Volume3.8x
Against its 20-day average, for the time of day.

Its industry

How TARA ranks in Biotech

TARA is #260 of 276 by Quality Score. The top three are shown with their scores, and more by name.

1KNSAKiniksa Pharmaceuticals International7/1418
2ABCLAbCellera Biologics6/1416
3OABIOmniAb9/1415
SYRESpyre TherapeuticsOpen for its score
TAKTakeda Pharmaceutical CompanyOpen for its score
TARSTarsus PharmaceuticalsOpen for its score
TECHBio-TechneOpen for its score
260TARAProtara Therapeutics1/14-7

When does TARA report earnings, and what happens after?

Expected to report Tue Nov 10, before the open (in 39 days). Not yet confirmed by the company.

+5.6%-0.7%+1.0%-4.9%

Nov 10Mar 10May 13Aug 11

Reported	When	Gap	Reaction	5 sessions
Aug 11, 2026Before open	Before open	-2.7%	-4.9%	-3.2%
May 13, 2026Before open	Before open	+2.9%	+1.0%	-15.7%
Mar 10, 2026Before open	Before open	+2.1%	-0.7%	-5.7%
Nov 10, 2025Before open	Before open	-0.2%	+5.6%	+28.4%

The gap is the next open against the close before the report; the reaction is where that session closed. TARA closed higher after 2 of its last 4. Past behavior, not a forecast.

Report dates and past reactions come from sessions that have already closed, so none of these figures move.

Filings

Who is trading TARA

TARA insider trades

One insider sold $882K across 1 filing in the last 6 months. No open-⁠market buys on record. The newest:

SellJesse Shefferman$882KCEO and Presidentat $4.09 on Jun 29, filed Jul 1

SellJesse SheffermanCEO and President$882Kat $4.09 on Jun 29, filed Jul 1

An insider has two business days to file a Form 4, so the trade is already days old when it becomes public. Shown as filed, with no delay.

The company

About Protara Therapeutics

Protara Therapeutics Inc is a clinical-stage biopharmaceutical company focused on advancing its therapies for the treatment of cancer and rare diseases. Its drug development pipeline includes: TARA-002, an investigational cell therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs); and IV Choline Chloride, an investigational phospholipid substrate replacement therapy, for patients receiving parenteral support, or PS, which includes both nutrition and fluids.

51 employeesNew York, NYprotaratx.com

Pro

Every line of the score, on every stock.

Real-time prices, no delay
Every line of TARA's score, with the points and the reason
All 14 checks on TARA and on all 2,958 stocks
Every stock ranked, with the chart
Every filing, and optional alerts on TARA

BreakawayJul 1Jesse Shefferman sold TARA$882K at $4.09, filed Jul 1

What a filing on TARA would have sent. Alerts are optional.

See all 14 checks on TARAFree for 24 hours. No account needed. Then keep going with a free account.

Questions

Straight Answers.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, trial included, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.

Where does the data come from?

Daily bars, quotes, reference data, headlines, and short interest come from Massive, formerly Polygon, a licensed market data vendor. The age of the quotes is shown at the top of every page. Insider trades, notable holders and profits come straight from the SEC. That means Form 4 filings, 13F filings and XBRL financial data on EDGAR. Government filings come from the public STOCK Act and Office of Government Ethics disclosures. The market-wide headlines on the market line also come from the public headline feeds CNBC, MarketWatch and Yahoo Finance publish, shown as the headline, the source and a link to the article. Splits, dividends, and the financial statements on each ticker page come from the vendor's reference data. The 8-K filings on EDGAR are read for the items that move a price. Five years of history is loaded for every stock. So the 200-day and 52-week checks rest on real history. Options flow is not part of the product.

Do I need an account?

Not for the first 24 hours. Tap any green button and you're in, with no email and no password. To keep going, create a free account with Google, Apple, or your email. There is no password to make up.

Is this investment advice?

No. It is a screening tool that scores stocks on the chart, the company's own results, and the news and filings. It does not know your situation and it is not a recommendation to buy or sell anything. Please do your own research.

The price, the score, the chart checks and readings, and the industry rank on this page are delayed at least 15 minutes. Filings are shown as filed, because a disclosure is already days or weeks old when it becomes public. Earnings dates and past reactions are settled sessions.